Letter by Nammas Regarding Article, “Should We Recommend Oral Anticoagulation Therapy in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting With a High HAS-BLED Bleeding Risk Score?”

With full interest, we read the article “Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?” by Ruiz-Nodar et al.1 In fact, I commend the authors for conducting this highly interesting piece of research using the newly pioneered HAS-BLED risk score for estimation of bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention. Evidently, the late-breaking innovation of the HAS-BLED bleeding risk score has paved the way for a long-awaited new insight to patients who need long-term oral anticoagulation (OAC) therapy.2 No wonder then that, very shortly …